Appendix C
Presentations and Visits

WASHINGTON, D.C., FEBRUARY 15–16, 2007

  • Department of Energy-National Nuclear Security Administration, Office of Global Threat Reduction, Nicole Nelson-Jean, DOE-NNSA, Office of North and South American Threat Reduction; Parrish Staples, DOE-NNSA, Office of Global Threat Reduction

  • Initiatives for the Development of Commercially Viable Mo-99 Production Methods Using LEU, Roy W. Brown, Council on Radionuclides and Radiopharmaceuticals (CORAR)

  • Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS-Nordion

  • OPAL (Open Pool Australian Lightwater) Reactor and Molybdenum-99, Therese Donlevy, Australian Nuclear Science and Technology Organisation (ANSTO)

  • Mallinckrodt’s Approach to HEU to LEU Conversion, Richard A. Roberts, Tyco Health Care/Mallinckrodt

  • The Security Imperative of Eliminating Commercial Use of HEU, Ed S. Lyman, Union of Concerned Scientists

  • Cost of Converting from HEU to LEU Targets for Medical Radioisotope Production, Frank von Hippel, Princeton University

  • IAEA Input to NAS Study on Medical Radioisotope Production without HEU, Ira Goldman, International Atomic Energy Agency (IAEA)



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 181
Appendix C Presentations and Visits WASHINGTON, D.C., FEBRUARY 15–16, 2007 • Department of Energy-National Nuclear Security Administration, Office of Global Threat Reduction, Nicole Nelson-Jean, DOE-NNSA, Office of North and South American Threat Reduction; Parrish Staples, DOE-NNSA, Office of Global Threat Reduction • Initiatives for the Development of Commercially Viable Mo-99 Production Methods Using LEU, Roy W. Brown, Council on Radionuclides and Radiopharmaceuticals (CORAR) • Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS-Nordion • OPAL (Open Pool Australian Lightwater) Reactor and Molybdenum- 99, Therese Donlevy, Australian Nuclear Science and Technology Organisa- tion (ANSTO) • Mallinckrodt’s Approach to HEU to LEU Conversion, Richard A. Roberts, Tyco Health Care/Mallinckrodt • The Security Imperative of Eliminating Commercial Use of HEU, Ed S. Lyman, Union of Concerned Scientists • Cost of Converting from HEU to LEU Targets for Medical Radio- isotope Production, Frank von Hippel, Princeton University • IAEA Input to NAS Study on Medical Radioisotope Production without HEU, Ira Goldman, International Atomic Energy Agency (IAEA) 

OCR for page 181
 APPENDIX C WASHINGTON, D.C., APRIL 10–11, 2007 • ANL Perspective on Conversion of Mo-99 Production from High to Low Enriched Uranium, George Vandegrift, Argonne National Labora- tory (ANL) • Commercial Production of Fission Mo-99 from LEU Targets in Argentina, Pablo Cristini and Marcelo Salvatore, Comisión Nacional de Energia Atómica (CNEA) and INVAP (Investigaciones Aplicadas Sociedad del Estado) • Commercial Production of Fission Radioisotopes from LEU Targets in Argentina, Pablo Cristini, CNEA • FDA’s Regulatory Role in Medical Isotope Production, Orhan Suleiman, Food and Drug Administration (FDA) • NRC’s Process for Licensing Exports of Highly Enriched Uranium (HEU) Medical Isotope Target Material, Stephen Dembek, U.S. Nuclear Regulatory Commission (NRC) • Highly Enriched Uranium (HEU) Exports for Medical Isotope Pro- duction, Edward T. Fei, NNSA • Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS Nordion • Mallinckrodt’s Mo-99 Process & Progress to LEU Conversion, Dale Simpson, Tyco Healthcare/Mallinckrodt • Ion Beam Applications: Past, Present, and Future, Henri Bonet, Institute National des Radioéléments (IRE) WASHINGTON, D.C., JUNE 11–12, 2007 • Global Threat Reduction Initiative–Reactor Conversion Program– Molybdenum-99 Production with LEU, Parrish Staples, DOE-NNSA • Drug Master File Development and FDA Filings for LEU-Produced Medical Radionuclides, Roy Brown, CORAR • Cardinal Health Nuclear Pharmacy Services, Jack Coffey, Cardinal Health • The Cost of Developing Imaging Agents for Routine Clinical Use, Adrian Nunn, Bracco Research • Status of IAEA Mo-99 Activities, Ira Goldman, IAEA • National Academy of Sciences: Medical Isotope Production Study, Ralph Butler, University of Missouri Research Reactor (MURR) • AECL’s Medical Isotope Production, Brian McGee, Atomic Energy of Canada Limited (AECL)

OCR for page 181
 APPENDIX C ST. LOUIS, MISSOURI, OCTOBER 15–17, 2007 • Supporting the Nation’s Nuclear Medicine Research–Update, Ralph A. Butler, MURR • Efforts by Current Commercial Mo-99 Producers to Examine LEU Technologies, Roy W. Brown, CORAR SITE VISITS • August 20–21, 2007: Visit to AECL Chalk River Laboratories (Chalk River, Ontario, Canada) and MDS Nordion (Kanata, Ontario, Canada) • December 17–18, 2007: Visit to ANSTO (Lucas Heights, Australia) • March 10–12, 2008: Visit to IRE (Fleures, Belguim), CERCA (Romans, France) and Mallinckrodt (Petten, the Netherlands) • June 5–6, 2008: Visit to CNEA (Buenos Aires, Argentina)